S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NASDAQ:AMED - Amedisys Stock Price, Forecast & News

$179.95
+13.94 (+8.40 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$162.15
Now: $179.95
$182.58
50-Day Range
$137.21
MA: $179.58
$202.02
52-Week Range
$106.65
Now: $179.95
$202.76
Volume245,554 shs
Average Volume272,267 shs
Market Capitalization$5.81 billion
P/E Ratio46.98
Dividend YieldN/A
Beta1.39
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2019, the company owned and operated 472 care centers in 38 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.
Read More
Amedisys logo

Industry, Sector and Symbol

Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.96 billion
Cash Flow$6.74 per share
Book Value$19.89 per share

Profitability

Net Income$126.83 million

Miscellaneous

Employees21,300
Market Cap$5.81 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.


Amedisys (NASDAQ:AMED) Frequently Asked Questions

How has Amedisys' stock been impacted by COVID-19 (Coronavirus)?

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AMED shares have increased by 5.6% and is now trading at $179.95. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amedisys?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys.

When is Amedisys' next earnings date?

Amedisys is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Amedisys.

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) announced its earnings results on Tuesday, February, 18th. The health services provider reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.93 by $0.01. The health services provider earned $500.70 million during the quarter, compared to analysts' expectations of $511.58 million. Amedisys had a net margin of 6.49% and a return on equity of 24.95%. The company's revenue for the quarter was up 15.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.91 EPS. View Amedisys' earnings history.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY20 earnings guidance on Tuesday, February, 18th. The company provided EPS guidance of $4.90-5.13 for the period, compared to the Thomson Reuters consensus estimate of $4.91. The company issued revenue guidance of $2.115-2.160 billion, compared to the consensus revenue estimate of $2.12 billion.

What price target have analysts set for AMED?

13 Wall Street analysts have issued 1 year price objectives for Amedisys' stock. Their forecasts range from $125.00 to $225.00. On average, they anticipate Amedisys' share price to reach $182.86 in the next twelve months. This suggests a possible upside of 1.6% from the stock's current price. View analysts' price targets for Amedisys.

Has Amedisys been receiving favorable news coverage?

News articles about AMED stock have trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a news impact score of -2.4 on InfoTrie's scale. They also gave news headlines about the health services provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutAmedisys.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in March. As of March 13th, there was short interest totaling 1,117,200 shares, an increase of 6.4% from the February 27th total of 1,050,000 shares. Based on an average trading volume of 292,900 shares, the short-interest ratio is currently 3.8 days. Approximately 3.5% of the company's shares are short sold. View Amedisys' Current Options Chain.

Who are some of Amedisys' key competitors?

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Cisco Systems (CSCO), CVS Health (CVS), Micron Technology (MU), Netflix (NFLX), Verizon Communications (VZ), QUALCOMM (QCOM), Adobe (ADBE) and Broadcom (AVGO).

Who are Amedisys' key executives?

Amedisys' management team includes the following people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 58)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 50)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 52)
  • Mr. David L. Kemmerly, Sr. VP of Gov. Affairs & Gen. Counsel (Age 56)
  • Ms. Sharon Brunecz, Chief HR Officer (Age 52)

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Who are Amedisys' major shareholders?

Amedisys' stock is owned by a number of retail and institutional investors. Top institutional investors include William Blair Investment Management LLC (3.32%), State Street Corp (3.12%), Alliancebernstein L.P. (2.17%), Riverbridge Partners LLC (2.06%), Norges Bank (1.69%) and Geode Capital Management LLC (1.46%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Kkr Credit Advisors (Us) Llc, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps. View institutional ownership trends for Amedisys.

Which institutional investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Bank of New York Mellon Corp, AQR Capital Management LLC, FMR LLC, Nuveen Asset Management LLC, Marshall Wace LLP, Rothschild & Co. Asset Management US Inc., and Marshall Wace North America L.P.. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz. View insider buying and selling activity for Amedisys.

Which institutional investors are buying Amedisys stock?

AMED stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Bank of America Corp DE, Castleark Management LLC, William Blair Investment Management LLC, British Airways Pensions Investment Management Ltd, Columbus Circle Investors, Renaissance Technologies LLC, and AXA. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps. View insider buying and selling activity for Amedisys.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $179.95.

How big of a company is Amedisys?

Amedisys has a market capitalization of $5.81 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe. View additional information about Amedisys.

What is Amedisys' official website?

The official website for Amedisys is http://www.amedisys.com/.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


MarketBeat Community Rating for Amedisys (NASDAQ AMED)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  384 (Vote Outperform)
Underperform Votes:  529 (Vote Underperform)
Total Votes:  913
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel